Overseed Secures $7.6M in Series A Funding for Groundbreaking Cannabis Pharmaceutical Research

French biotech company Overseed recently announced the successful raise of $7,600,000 in funding. The company has obtained its license from the ANSM, making it the first of its kind in France to begin research and development on cannabis production for pharmaceutical purposes. Overseed's mission is to leverage its expertise in genetics, agronomy, organic chemistry, and pharmaceuticals to become a leader in the production of therapeutic cannabis. The funding will be used to produce GACP and GMP certified dried flowers, full spectrum extracts, and pharmaceutical grade active ingredients for laboratories. By focusing on ensuring production sovereignty, collaborating closely with medical professionals, and conducting rigorous scientific studies, Overseed aims to meet the expectations of patients and the health industry for high-quality and certified cannabis products. With a strong emphasis on people, product quality, and value creation, Overseed is set to make significant strides in the field of therapeutic cannabis production.